OBJECTIVE: To study the prevalence of lower urinary tract symptoms (LUTS) and incontinence in late-onset Pompe disease (LOPD) Methods: Adult LOPD patients seen at the Duke Pompe Clinic were prospectively recruited and asked to complete validated questionnaires on LUTS and incontinence as part of an IRB-approved study. Patient demographics as well as previous urologic history were reviewed. RESULTS: 35 patients with LOPD were included in the study (17 males and 18 females). The median age was 51.8 (range 18-72 years of age). Of these patients, 27/35 were receiving enzyme replacement therapy (ERT) with median duration of 54 months (range 5-88 months). In the male patients, 9/17 (53%) described their stream as dribbling, weak, or intermittent, and 9/17 (53%) complained of post-void dribbling. In addition 38% of the men were unable to stop their urination midstream. In the female patients, the most common complaint was urinary incontinence, reported in 14/18 (78%). In addition, 7/18 (39%) complained of post-void dribbling, and 47% were unable to stop their urination midstream. Bowel incontinence was reported in 45% of patients. There was a significant association between urinary symptoms and lower extremity function scores and duration of ERT (p = 0.005 and p = 0.04, respectively) CONCLUSIONS: This is the first study in a large cohort of LOPD patients that demonstrates LUTS and incontinence occur at a high rate. This study emphasizes the spectrum of LOPD is beyond isolated gross motor and pulmonary involvement and has a significant effect on the lower urinary tract.
OBJECTIVE: To study the prevalence of lower urinary tract symptoms (LUTS) and incontinence in late-onset Pompe disease (LOPD) Methods: Adult LOPD patients seen at the Duke Pompe Clinic were prospectively recruited and asked to complete validated questionnaires on LUTS and incontinence as part of an IRB-approved study. Patient demographics as well as previous urologic history were reviewed. RESULTS: 35 patients with LOPD were included in the study (17 males and 18 females). The median age was 51.8 (range 18-72 years of age). Of these patients, 27/35 were receiving enzyme replacement therapy (ERT) with median duration of 54 months (range 5-88 months). In the male patients, 9/17 (53%) described their stream as dribbling, weak, or intermittent, and 9/17 (53%) complained of post-void dribbling. In addition 38% of the men were unable to stop their urination midstream. In the female patients, the most common complaint was urinary incontinence, reported in 14/18 (78%). In addition, 7/18 (39%) complained of post-void dribbling, and 47% were unable to stop their urination midstream. Bowel incontinence was reported in 45% of patients. There was a significant association between urinary symptoms and lower extremity function scores and duration of ERT (p = 0.005 and p = 0.04, respectively) CONCLUSIONS: This is the first study in a large cohort of LOPD patients that demonstrates LUTS and incontinence occur at a high rate. This study emphasizes the spectrum of LOPD is beyond isolated gross motor and pulmonary involvement and has a significant effect on the lower urinary tract.
Authors: F Martiniuk; A Chen; A Mack; E Arvanitopoulos; Y Chen; W N Rom; W J Codd; B Hanna; P Alcabes; N Raben; P Plotz Journal: Am J Med Genet Date: 1998-08-27
Authors: A G Bijvoet; E H van de Kamp; M A Kroos; J H Ding; B Z Yang; P Visser; C E Bakker; M P Verbeet; B A Oostra; A J Reuser; A T van der Ploeg Journal: Hum Mol Genet Date: 1998-01 Impact factor: 6.150
Authors: Nancy N Maserejian; Shan Chen; Gretchen R Chiu; Andre B Araujo; Varant Kupelian; Susan A Hall; John B McKinlay Journal: J Urol Date: 2013-07-10 Impact factor: 7.450
Authors: Jennifer T Anger; Christopher S Saigal; Lynn Stothers; David H Thom; Larissa V Rodríguez; Mark S Litwin Journal: J Urol Date: 2006-11 Impact factor: 7.450
Authors: Nancy N Maserejian; Shan Chen; Gretchen R Chiu; Carrie G Wager; Varant Kupelian; Andre B Araujo; John B McKinlay Journal: Urology Date: 2013-07-19 Impact factor: 2.649
Authors: Su Xu; Yi Lun; Michelle Frascella; Anadina Garcia; Rebecca Soska; Anju Nair; Abdul S Ponery; Adriane Schilling; Jessie Feng; Steven Tuske; Maria Cecilia Della Valle; José A Martina; Evelyn Ralston; Russell Gotschall; Kenneth J Valenzano; Rosa Puertollano; Hung V Do; Nina Raben; Richie Khanna Journal: JCI Insight Date: 2019-03-07
Authors: Allison M Keeler; Donghai Liu; Marina Zieger; Lang Xiong; Jeffrey Salemi; Karl Bellvé; Barry J Byrne; David D Fuller; Ronghua ZhuGe; Mai K ElMallah Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-03-23 Impact factor: 5.464